血管紧张素转化酶多态性与北京降压0号长期降压效果的关系

Relationship between the efficacy of Beijing hypotensive No 0 and angiotensin converting enzyme gene I/D polymorphism

目的:探讨不同血管紧张素转化酶(ACE)基因插入/缺失(I/D)多态性的基因型的原发性高血压(EH)患者对北京降压0号治疗的长期反应性。方法:根据ACE I/D基因多态性,将EH患者分为II组(16例),ID组(11例)及DD组(15例),共42例。使用北京降压0号1片/d,共1年,观察降压疗效。结果:II组显效10例,有效5例,总有效率93.8%;ID组显效5例,有效4例,总有效率81.8%;DD组显效11例,有效2例,总有效率86.7%,控制率分别为75.0%、72.7%、60.0%,各组疗效差异无统计学意义(P>0.05),3组平均血压下降值比较,舒张压下降值II组高于ID组(P<0.05),其余均差异无统计学意义。结论:ACE I/D基因多态性对北京降压0号治疗EH的长期效果无影响。

Objective： To study the correlation between angiotensin converting enzyme（ACE） genotypes and the long-term antihypertensive effects of Heijing hypotensive No 0 on essential hypertensive patients. Method： Forty two patients were treated with Beijing hypotensive No 0 , 1 tablet per day for one year . The subjects were grouped into Ⅱ, ID, and DD genotypes, and antihypertensive effects were compared among different ACE genotypes, Result：After one year treatment, the total effective rate in three groups were Ⅱ 93.8%, ID 81.8%, DD 86.7% ,and the control rate were 75.0%, 72.7%, 60.0% ,There was no significant difference in the total effective rate and control rate among these three groups, the blood pressure decreasing in DBP was higher in Ⅱ than ID （ P 〈0.05）. Conclusion：There was no difference between EH patients carrying different ACE genotypes responded to hypotensive No 0 .